Eczema breakthrough: kids may be able to cut back on pricey shots
NCT ID NCT06116526
First seen Jan 12, 2026 · Last updated Apr 30, 2026 · Updated 19 times
Summary
This study looks at whether children aged 1 to 17 with controlled eczema can safely take less dupilumab or stop it entirely. About 30 kids who have been on the drug for at least a year will be randomly assigned to reduce their dose or stop treatment. The goal is to see if they can maintain good skin control without needing to go back to the full dose or add other medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins Univerisity
RECRUITINGBaltimore, Maryland, 21210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.